MoneyWorks4Me

Yatharth Hospital & Trauma Care Services Ltd (YATHARTH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543950 NSE: YATHARTH Hospital & Healthcare Services | Small Cap | Yatharth Hospital Share Price

₹990.60 27.85 (2.89%)

As on 04-Sep'26 16:59

Yatharth Hospital & Trauma Care Services Ltd (YATHARTH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543950 NSE: YATHARTH Hospital & Healthcare Services | Small Cap | Yatharth Hospital Share Price

₹990.60 27.85 (2.89%)

As on 04-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹9,545 Cr.
Current Price
₹990.6
52-Week Low / High
₹538 / 1,025
TTM EPS
₹10
TTM Sales
₹636 Cr.
Book Value per Share
₹171
P/E Ratio
98.95
Higher than its 5-year historical median
Industry PE
99.7
Price to Book (P/B)
5.79
Higher than its 5-year historical median
Price to Sales (P/S)
15.02
Higher than its 5-year historical median
EV/EBITDA
54.81
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
6.07%
Underperforms industry median
Return on Capital Employed (ROCE)
8.22%
Underperforms industry median
Return on Assets (ROA)
5.25%
Operating Profit Margin
24.6%
Net Profit Margin
16.12%
Gross Profit Margin
26.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
29.66%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
9.96%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
8.8%
Asset Quality
Promoter Holding
55.80%
Pledged shares (%) of Promoter's holding (%)
9.59%
Reserves
₹1,551 Cr.
Equity
₹96.4 Cr.
Face Value
₹10
All Time Low / High
₹304.00 / 1024.95

Yatharth Hospital & Trauma Care Services stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Somewhat Good

Valuation

Overvalued

Price Trend

Strong
Q.1 Is Yatharth Hospital & Trauma Care Services Ltd a good quality company?
Yatharth Hospital & Trauma Care Services Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Yatharth Hospital & Trauma Care Services Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Yatharth Hospital & Trauma Care Services Ltd vs industry peers?
Yatharth Hospital & Trauma Care Services Ltd revenue CAGR is 29.15%, compared to the industry median CAGR of 3.54%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Yatharth Hospital & Trauma Care Services Ltd?
Promoters hold 55.80% of the Yatharth Hospital & Trauma Care Services Ltd, with 9.59% of their stake pledged, indicating low pledge risk.
Q.1 Stock return of Yatharth Hospital & Trauma Care Services Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 39.25% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Yatharth Hospital & Trauma Care Services Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % 0%0%7.1%9.7%17.9%37.2%37.3%21.1%10.4%8.2%-
Value Creation
Index
NANA-0.5-0.30.31.81.70.5-0.3-0.4-

Growth Parameters

Sales 00102133165299372420456592636
Sales YoY Gr.-NANA30.3%24.1%81.3%24.4%13%8.7%29.7%-
Adj EPS 000.40.11.96.49.89.89.19.910
YoY Gr.-NANA-72.7%1466.7%241.5%52.7%-0.2%-7%8.8%-
BVPS (₹) 008.58.610.617.126.997.5158.3168.1171
Adj Net
Profit
002.90.812.342.164.28487.795.496
Cash Flow from Ops. 001923.525.826.825.61694.594.6-
Debt/CF from Ops. 006.34.844.14.40.202.4-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NA29.2%16.8%29.7%
Adj EPS NA39.4%0.3%8.8%
BVPSNA73.8%84.2%6.2%
Share Price - - 38.9% 26.7%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
005.21.419.646.544.616.67.46.15.9
Op. Profit
Mgn %
0019.423.72728.528.628.32924.622.5
Net Profit
Mgn %
002.90.67.514.117.32019.216.115.2
Debt to
Equity
002.221.510.7000.1-
Working Cap
Days
000758697128260494506137
Cash Conv.
Cycle
00092542618811797116

Valuation of Yatharth Hospital - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.0013.8113.8115.3310.7310.739.59
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales102133165299372420456592
Operating Expenses + 82101120214265301324446
Manufacturing Costs37505490123148119174
Material Costs9131828293786115
Employee Cost 18223257576982114
Other Costs 1817173957463742
Operating Profit 20314585106119132146
Operating Profit Margin (%) 19.4%23.7%27.0%28.5%28.6%28.3%29.0%24.6%
Other Income + 0011214923
Exceptional Items 00000000
Interest 7141313106411
Depreciation 815141313131930
Profit Before Tax 63186086113119127
Tax 3251821293232
Profit After Tax 31124264848895
PAT Margin (%) 2.9%0.6%7.5%14.1%17.3%20.0%19.2%16.1%
Adjusted EPS (₹)0.40.11.96.49.89.89.19.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 5656691121768371,5251,620
Share Capital 1616166666869696
Reserves 394053461117511,4291,523
Debt +12010296858620199
Long Term Debt12010292707620199
Short Term Debt0041510000
Minority Interest00000000
Trade Payables1211131611121148
Others Liabilities 10323473542895137
Total Liabilities 1972022112863268781,6312,004

Fixed Assets

Net Fixed Assets +146134132122121133161393
Gross Block191194209212223248283541
Accumulated Depreciation44597690102116122148
CWIP 00000015318
Investments 283334474767234534
Inventories23323499
Trade Receivables1318327686143171206
Cash Equivalents 011213227299201
Others Assets 712103657304603643
Total Assets 1972022112863268781,6312,004
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 1924262726169595
PBT 83186086113119127
Adjustment 112827252162225
Changes in Working Capital 2-5-18-49-49-67-34-14
Tax Paid -2-2-0-9-32-36-13-44
Cash Flow From Investing Activity + -39-8-4-18-9-167-557-383
Capex -1-3-3-6-8-34-203-115
Net Investments -12-5-0-0-0-125-124
Others -260-1-130-8-354-292
Cash Flow From Financing Activity + 21-20-23-7-6241602215
Net Proceeds from Shares 400005776000
Net Proceeds from Borrowing 22-1740-1-740199
Interest Paid -5-13-12-12-9-4-0-3
Dividend Paid 00000000
Others 011-1444-258220
Net Cash Flow 2-4-111189140-73
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)5.231.4219.6346.4944.5916.587.426.07
ROCE (%)7.089.7317.9137.1937.3221.0610.428.22
Asset Turnover Ratio0.520.670.81.21.210.70.360.33
PAT to CFO Conversion(x)6.33242.170.640.410.191.081
Working Capital Days
Receivable Days45.8042.8055.406679.7099.70125.60116
Inventory Days8.106.705.903.102.703.105.305.60
Payable Days450.50319.80249.80189.50171.50109.7048.2094.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Yatharth Hospital & Trauma Care Services Ltd FAQs

The current trading price of Yatharth Hospital on 04-Sep-2026 16:59 is ₹990.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Sep-2026 the market cap of Yatharth Hospital stood at ₹9,544.9 Cr

The latest P/E ratio of Yatharth Hospital as of 03-Sep-2026 is 98.95.

The latest P/B ratio of Yatharth Hospital as of 03-Sep-2026 is 5.79.

The 52-week high of Yatharth Hospital is ₹1,025 and the 52-week low is ₹538.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Yatharth Hospital is ₹636 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Yatharth Hospital & Trauma Care Services Ltd is a average quality company.

The key valuation ratios of Yatharth Hospital & Trauma Care Services Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Yatharth Hospital & Trauma Care Services Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The company’s hospitals have been designed to comply with international quality standards with its Noida Extension Hospital accredited by Joint Commission International (JCI), USA and all its hospitals accredited by the National Accreditation Board for Hospitals (NABH). The company’s hospitals have been built on a foundation of talent, trust, technology, service and infrastructure. 

All of its hospitals offer spacious suites along with modern deluxe and super deluxe rooms, and comfortable patient waiting areas. The company’s diagnostic areas are designed with the goals of providing patient-friendly, spacious and relaxing environments. The company has advanced medical equipment such as Azurion catheterization laboratory and are equipped with the latest robotics surgical equipments like the DaVinci, Mako and Cuvis, 1.5 Tesla whole-body MRI with optical digital broadband and embedded express coil technology for minimal patient repositioning and advanced non-contrast MR Angiography, 128 slice CT scan, endo bronchial ultrasound, nerve conduction velocity (NCV), advanced surgical equipment including Thulium Uro laser, flexible scope, advance laparoscope, advance microscopes, Cusa set. These advanced equipments provide for a better and more accurate diagnosis, as well as insight into the surgical procedure, which increases the surgical success rate.

Some of its modular operation theatres are equipped with high efficiency particulate air (HEPA) filters and laminar flow, operating microscopes with image intensifiers. The company’s in-house diagnostic radiology setup and diagnostic labs are well-equipped centres with comprehensive diagnostic capabilities including, haematology, biochemistry, microbiology, molecular biology and histopathology along with 24x7 in-house pharmacy shops.

Business area of the company 

The company is engaged in the business of providing healthcare services, operating hospitals and other allied services, as may be required for the provision of healthcare services. The company has one hospital each in Noida and Greater Noida.

Awards and Accreditations

  • 2020: Recognized as Emerging Hospital Chain in Delhi NCR by Medico Trip India.
  • 2020: Awarded 1stPrize in Swachhta Ranking Competition in the category of Swachh Hospital (for the quarter ended June 2019) in compliance with Swachh Survekshan League 2020 by Noida Authority.
  • 2020: Awarded 1st Rank in Swachhta Ranking Competition in the category of Swachh Hospital (for the quarter ended September 2019) in compliance with Swachh Survekshan League 2020 by Noida Authority.
  • 2021: Certificate of appreciation as ‘Heroes’-Beyond the Call of Duty from Tata Consultancy Services.
  • 2021: Covid Thank You Award by Niva Bupa.
  • 2021: 5 star grading by Infomerics Analysts & Research Private Limited for its hospitals located at Noida, Noida Extension and Greater Noida.
  • 2023: Awarded UP Ratan Samman by Dainik Jagran Inext.
  • 2024-25: Awarded the Best Brand for Excellence in Healthcare at the Economic Times (ET) Edge Best Brands Conclave, in recognition to its consistent innovation and customer-centric approach
  • 2024-25: Noida Extension Hospital accredited by Joint Commission International (JCI) – the first hospital in Uttar Pradesh and seventh in North India to receive this prestigious global accreditation

Milestones

  • 2008: Incorporated the Company and commenced operations
  • 2010: Established first hospital in Greater Noida
  • 2013: Established its second hospital, a 250-bed hospital facility in Noida
  • 2018: Expanded its first hospital, Greater Noida hospital to 400 beds
  • 2019: Commenced operations of its third hospital in, Noida Extension, in May 2019, following the acquisition of its subsidiary AKS in 2016
  • 2022: Acquired its fourth hospital, the Jhansi Orchha hospital, adding 305 beds, through the acquisition of Ramraja Multispeciality Hospital
  • 2023: Listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE)
  • 2024: Acquired its fifth hospital, in Faridabad, Delhi NCR, adding 200 beds
  • 2025: Successfully acquired two hospital, first in Model Town , Delhi and second in Sector 20, Faridabad, Haryana

You have 29 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: